Concordance of retinopathy and nephropathy over time in Type 1 diabetes: An analysis of data from the Diabetes Control and Complications Trial

Diabetic Medicine

Volumn 30, Issue 11, 2013, Pages 1333-1341

  Kramer, C K ^a,b   Retnakaran, R ^a,b,c  

^a MOUNT SINAI HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; EARLY TREATMENT DIABETIC RETINOPATHY STUDY SCORE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SCORING SYSTEM; URINARY EXCRETION;

ADULT; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84885901140     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12296     Document Type: Article

References (30)

1. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005). Arch Intern Med 2009; 169: 1307-1316.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
3. Genuth S, Lipps J, Lorenzi G, Nathan DM, Davis MD, Lachin JM et al. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563-2569.
4. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995; 12: 482-487.
5. Chen YH, Chen HS, Tarng DC. More impact of microalbuminuria on retinopathy than moderately reduced GFR among type 2 diabetic patients. Diabetes Care 2012; 35: 803-808.
6. Romero-Aroca P, Baget-Bernaldiz M, Reyes-Torres J, Fernandez-Ballart J, Plana-Gil N, Mendez-Marin I et al. Relationship between diabetic retinopathy, microalbuminuria and overt nephropathy, and 20-year incidence follow-up of a sample of Type 1 diabetic patients. J Diabetes Complications 2012; 26: 506-512.
7. Lovestam-Adrian M, Agardh E, Agardh CD. The incidence of nephropathy in type 1 diabetic patients with proliferative retinopathy: a 10-year follow-up study. Diabetes Res Clin Pract 1998; 39: 11-17.
8. The Diabetes Control and Complications Trial. Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986; 35: 530-545.
9. Diabetes Control and Complications Trial. Update. DCCT Research Group. Diabetes Care 1990; 13: 427-433.
10. The Diabetes Control and Complications Trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995; 113: 36-51.
11. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720.
12. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Moharram OA, Kangave D. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol 2001; 24: 1-11.
13. Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994; 43: 441-446.
14. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25: 859-864.
15. Klein R, Zinman B, Gardiner R, Suissa S, Donnelly SM, Sinaiko AR et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes 2005; 54: 527-533.
16. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163.
17. Vigstrup J, Mogensen CE. Proliferative diabetic retinopathy: at-risk patients identified by early detection of microalbuminuria. Acta Ophthalmol (Copenh) 1985; 63: 530-534.
18. Paterson AD, Bull SB. Does familial clustering of risk factors for long-term diabetic complications leave any place for genes that act independently? J Cardiovasc Transl Res 2012; 5: 388-398.
19. Harris EL, Sherman SH, Georgopoulos A. Black-white differences in risk of developing retinopathy among individuals with type 2 diabetes. Diabetes Care 1999; 22: 779-783.
20. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. J Am Med Assoc 1992; 268: 3079-3084.
21. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 1829-1839.
22. Trevisan R, Viberti G. Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 1995; 126: 342-349.
23. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9: 1653-1663.
24. Pettersson-Fernholm K, Frojdo S, Fagerudd J, Thomas MC, Forsblom C, Wessman M et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int 2006; 69: 1880-1884.
25. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994; 43: 1358-1364.
26. Feldt-Rasmussen B, Dinesen B, Deckert M. Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 1985; 45: 539-544.
27. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-2293.
28. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-1408.
29. Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 2007; 30: 1998-2000.
30. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36: S11-66.